background
banner

MAXALT 5mg Price

Active Substance: Rizatriptan (as benzoate).

77
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on MAXALT 5mg page.
This medicine contains an important and useful components, as it consists of
Rizatriptan (as benzoate)is available in the market in concentration

Name

Rizatriptan

Precaution

Elderly; mild to moderate hepatic or renal impairment; coronary artery disease; pregnancy, lactation. May cause drowsiness. History of seizures. Ensure an interval of at least 24 hr after stopping an ergotamine compound and starting a serotonin (5-HT1) agonist. Lactation: Unknown; use with caution in breastfeeding

Indication

Acute migraine attacks

Contra indication

History of MI, peripheral vascular disease, transient ishaemic attack, ischaemic heart disease or Prinzmetal's angina; uncontrolled hypertension; basilar or hemiplegic migraine; severe hepatic or renal impairment. Adolescent <18 yr.

Side Effect

>10% Drowsiness (13-30%, dose related),Fatigue (13-30%, dose related),Dizziness (11-15%) 1-10% Dizziness (4-9%),Somnolence (4-8%),Fatigue (4-7%; dose related),Nausea (4-6%),Asthenia (1-5%),Hot flashes (1-5%),Paresthesia (3-4%),Dry mouth (3%),Chest pain (2-3%),Pain/pressure in chest, neck, throat, jaw (<2%),Headache (<2%),Dyspnea (>1%),Hypoesthesia (>1%),Palpations (>1%),Skin flushing (>1%) <1% Tachycardia,Angioedema,Wheezing,Hypertensive crisis,Bradycardia,Hallucination,Epidermal necrolysis,Hearing impairment,Arrhythmias,Myocardial infarction and coronary artery vasospasm in patients with CAD risk factors Potentially Fatal: Toxic epidermal necrolysis.

Pregnancy Category ID

3

Mode of Action

Rizatriptan is a selective serotonin (5-HT1) agonist in cranial arteries responsible for vasoconstriction and reduction of inflammation associated with antidromic neuronal transmission.

Interaction

Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome. Potentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration

banner

Contact Us / Report Error

Please contact us for any inquiries or report any errors.

Or U can Send Us Email: [email protected]